Fingolimod (FTY720), an immunomodulator that acts on sphingosine-1-phosphate receptors, is the first oral disease-modifying agent to be approved by the US FDA for the treatment of relapsing forms ...

In addition, women were even less likely to receive high-efficacy treatments such as natalizumab, anti-CD20 antibodies, or ...

Novartis' small molecule FTY720 (fingolimod), now in phase 3, is a potential threat to Biogen Idec's lucrative multiple sclerosis (MS) franchise. But in June Novartis reported that two phase 3 ...

Among 282 patients with pediatric-onset MS, 39% started high-efficacy therapy early (at ages 12-17), and 61% started late ...

A study has revealed significant therapeutic inertia in the treatment of women with multiple sclerosis (MS), highlighting ...

This leads some people with MS to wonder if they should get vaccinated against COVID-19. According to the National Multiple ...

Still in the game, but just barely, is Basel–based Novartis' S1P1 modulator FTY720 (fingolimod), which has run into serious safety issues in pivotal testing. Table 1 Selected MS therapies in ...

Medically reviewed by Gurdeep S. Sareen, PharmDMedically reviewed by Gurdeep S. Sareen, PharmD Even though multiple sclerosis ...

To address the unmet need for a cure for RTT, the therapeutic potential of adult Neural Precursor Cells (NPCs) was ...

A new study reveals how gender disparities cause therapeutic inertia in MS treatment for women, highlighting delays and ...

This is really important, because there have been case reports of patients experiencing relapses with natalizumab and fingolimod when they've discontinued the medication. That's why it's important for ...